<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618420</url>
  </required_header>
  <id_info>
    <org_study_id>17-0820</org_study_id>
    <nct_id>NCT03618420</nct_id>
  </id_info>
  <brief_title>Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function</brief_title>
  <acronym>CASPER</acronym>
  <official_title>CASPER Study: Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from&#xD;
      cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality&#xD;
      in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia&#xD;
      and hypertension, are beneficial, but only partially protect against DKD.&#xD;
&#xD;
      Hyperfiltration is common in youth with T1D, and predicts progressive DKD. Hyperfiltration is&#xD;
      also associated with early changes in intrarenal hemodynamic function, including increased&#xD;
      renal plasma flow (RPF) and glomerular pressure. Intrarenal hemodynamic function is strongly&#xD;
      influenced by the renin-angiotensin-aldosterone system (RAAS), which is also considered a key&#xD;
      player in the pathogenesis of DKD. Preliminary data demonstrate differences in intrarenal&#xD;
      hemodynamic function and RAAS activation in early and advanced DKD in T1D. However, the&#xD;
      pathophysiology contributing to the differences observed in RAAS activation and intrarenal&#xD;
      hemodynamic function in T1D are poorly defined Animal research demonstrates that arginine&#xD;
      vasopressin (AVP) acts directly to modify intrarenal hemodynamic function, but also&#xD;
      indirectly by activating RAAS. Preliminary data suggest that elevated copeptin, a marker of&#xD;
      AVP, which predicts DKD in T1D adults, independently of other risk factors. However, no human&#xD;
      studies to date have examined how copeptin relates to intrarenal hemodynamic function in&#xD;
      early DKD in T1D. A better understanding of this relationship is critical to inform&#xD;
      development of new therapies targeting the AVP system in T1D. Accordingly, in this study, the&#xD;
      investigators propose to define the relationship between copeptin and intrarenal hemodynamics&#xD;
      in early stages of DKD, by studying copeptin levels, renal plasma flow, and glomerular&#xD;
      filtration in youth (n=50) aged 12-21 y with T1D duration &lt; 10 y.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 19, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All study participants will receive the same intervention.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Copeptin Levels</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by fasting blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by PAH clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by iohexol clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Perfusion</measure>
    <time_frame>10 min</time_frame>
    <description>Measured by Arterial Spin Labeling (ASL) MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Oxygenation</measure>
    <time_frame>60 min</time_frame>
    <description>Measured by Blood Oxygen Level Dependent (BOLD) MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Nephropathy</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Juvenile Diabetes</condition>
  <condition>Diabetes Mellitus Complication</condition>
  <condition>Autoimmune Diabetes</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminohippurate Sodium Inj 20%</intervention_name>
    <description>Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)</description>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <other_name>Aminohippuric acid</other_name>
    <other_name>Para-aminohippurate</other_name>
    <other_name>Sodium 4-amino hippurate (PAH) inj 20% 2g/10 mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol Inj 300 mg/mL</intervention_name>
    <description>Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
    <arm_group_label>Clinical Investigation</arm_group_label>
    <other_name>omnipaque 300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Antibody+ T1D with &lt;10 yr duration&#xD;
&#xD;
          -  Age 12-21 years&#xD;
&#xD;
          -  BMI ≥ 5%ile&#xD;
&#xD;
          -  Weight&lt;350 lbs and &gt; 57 lbs.&#xD;
&#xD;
          -  No anemia&#xD;
&#xD;
          -  HbA1c &lt;12%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe illness, recent diabetic ketoacidosis (DKA)&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt;60ml/min/1.73m2 or creatinine &gt; 1.5mg/dl&#xD;
             or history of ACR≥300mg/g&#xD;
&#xD;
          -  Anemia or allergy to shellfish or iodine&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  MRI scanning contraindications (claustrophobia, implantable devices, &gt;350 lbs)&#xD;
&#xD;
          -  Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB),&#xD;
             diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or&#xD;
             aspirin, sulfonamides, procaine, thiazolsulfone or probenecid, atypical antipsychotics&#xD;
             and steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petter Bjornstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Denver</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03618420/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clinical Investigation</title>
          <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinical Investigation</title>
          <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Copeptin Levels</title>
        <description>Measured by fasting blood draw</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Investigation</title>
            <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
          </group>
        </group_list>
        <measure>
          <title>Copeptin Levels</title>
          <description>Measured by fasting blood draw</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effective Renal Plasma Flow (ERPF)</title>
        <description>Measured by PAH clearance</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Investigation</title>
            <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Renal Plasma Flow (ERPF)</title>
          <description>Measured by PAH clearance</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glomerular Filtration Rate (GFR)</title>
        <description>Measured by iohexol clearance</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Investigation</title>
            <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR)</title>
          <description>Measured by iohexol clearance</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Perfusion</title>
        <description>Measured by Arterial Spin Labeling (ASL) MRI</description>
        <time_frame>10 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Investigation</title>
            <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Perfusion</title>
          <description>Measured by Arterial Spin Labeling (ASL) MRI</description>
          <units>ml/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Oxygenation</title>
        <description>Measured by Blood Oxygen Level Dependent (BOLD) MRI</description>
        <time_frame>60 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Investigation</title>
            <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Oxygenation</title>
          <description>Measured by Blood Oxygen Level Dependent (BOLD) MRI</description>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over 1 month post procedure (since this was a cross-sectional study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clinical Investigation</title>
          <description>All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.&#xD;
Aminohippurate Sodium Inj 20%: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)&#xD;
Iohexol Inj 300 mg/mL: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache/lightheadedness/nausea</sub_title>
                <description>Participant experienced headache and lightheadedness during screening visit when blood draw to obtain screening labs was attempted. This is a known risk which is included in the consent form.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <description>Participant experienced vasovagal syncope as a result of anxiety and PIV placement at the beginning of study visit; known risk which is included in the consent form.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Petter Bjornstad, M.D., Assistant Professor of Pediatrics and Medicine</name_or_title>
      <organization>University of Colorado School of Medicine</organization>
      <phone>7207774659</phone>
      <email>petter.bjornstad@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

